Registry for evaluating the Precision Medicine Molecular Tumor Board
UWCCC Precision Medicine Molecular Tumor Board Registry
This study is testing how genetic testing of tumors can help doctors make better treatment decisions for patients with blood cancers and solid tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Trial ID | NCT03023202 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the clinical utility of the Precision Medicine Molecular Tumor Board (PMMTB) by tracking patient outcomes related to hematologic and solid neoplasms. Participants will undergo genetic testing of their tumors, and the study will evaluate how the insights gained from the PMMTB can inform treatment decisions. The study is designed to gather data that may enhance personalized medicine approaches in oncology.
Who should consider this trial
Good fit: Ideal candidates include adults with clinically suspected or confirmed solid or hematological malignancies who are undergoing genetic testing.
Not a fit: Patients under 18 years old will not benefit from this study due to exclusion criteria.
Why it matters
Potential benefit: If successful, this study could improve treatment strategies for patients with cancer by utilizing genetic insights to tailor therapies.
How similar studies have performed: Other studies utilizing molecular tumor boards have shown promise in improving patient outcomes, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically suspected or histologically confirmed solid or hematological malignancy * Undergoing genetic testing of tumor * Ability to understand written informed consent document * Willingness to sign written informed consent document Exclusion Criteria: * Pediatric patients (age\<18 years) will be excluded due to a lack of expertise on the molecular tumor committee
Where this trial is running
Madison, Wisconsin
- University of Wisconsin Carbone Cancer Center — Madison, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Dustin Deming, MD — University of Wisconsin, Madison
- Study coordinator: Cancer Connect
- Email: clinicaltrials@cancer.wisc.edu
- Phone: 8006228922
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.